Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bristol Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
July 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
July 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
July 08, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
June 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Dividend
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
June 13, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
June 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
May 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
May 29, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
May 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
May 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
May 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
May 16, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
May 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
May 10, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
May 07, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
May 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
April 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
April 25, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
April 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.